XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Net revenues $ 3,978 $ 4,093 $ 12,206 $ 12,420
Cost of sales 2,126 2,264 6,528 6,841
Gross profit 1,852 1,830 5,678 5,579
Research and development expenses 258 240 704 778
Selling and marketing expenses 605 595 1,815 1,908
General and administrative expenses 279 285 846 873
Intangible assets impairments 509 177 1,278 1,206
Goodwill impairment 4,628 0 4,628 0
Other assets impairments, restructuring and other items (98) 160 404 263
Legal settlements and loss contingencies 21 468 10 1,171
Other income (8) (14) (30) (29)
Operating (loss) income (4,342) (81) (3,978) (591)
Financial expenses, net 117 211 565 635
Income (loss) before income taxes (4,459) (292) (4,543) (1,226)
Income taxes (benefit) 16 11 (147) (159)
Share in (profits) losses of associated companies, net (136) 4 (135) 8
Net income (loss) (4,340) (307) (4,261) (1,076)
Net income (loss) attributable to non-controlling interests 10 7 (121) 33
Net income (loss) attributable to Teva $ (4,349) $ (314) $ (4,140) $ (1,108)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ (3.97) $ (0.29) $ (3.78) $ (1.02)
Diluted $ (3.97) $ (0.29) $ (3.78) $ (1.02)
Weighted average number of shares (in millions):        
Basic 1,096 1,092 1,095 1,091
Diluted 1,096 1,092 1,095 1,091